Small caps round-up: Epistem, Stadium Group, Trading Emissions

Biotechnology firm Epistem Hldings said it had received the go-ahead to sells its new tuberculosis product in EEA member state markets. The firm said its Genedrive units provided a major advance in next generation molecular diagnostic testing. Epistem is now preparing regulatory submissions for India, which has the largest number of TB sufferers in the world.Stadium Group said sales in the first half were below last year due to the underlying economic environment and the impact of the company's decision to withdraw from a number of low margin legacy contracts. However, it said this had been partially offset by a number of important new business wins and continuing cost reduction activity. It added that the firm was pursuing a number of potential acquisitions.Trading Emissions slipped on Thursday after it released details of negotiation in China to reduce its losses and liabilities arising from commitments to purchase Certified Emission Reduction certificates at fixed prices, which remained above prevailing market prices. It said eight out of 44 ERPAs had been renegotiated with project owners, but 16 project owners had, to date, declined to commence renegotiations. Shares dropped 2% on the news.MM